The Wyss Institute for Biologically Inspired Engineering at Harvard University was formed based on the recognition that breakthrough discoveries cannot change the world if they never leave the laboratory. The Institute's mission is to discover the biological principles that Nature uses to build living things, and to harness these insights to create biologically inspired engineering innovations to advance human health and create a more sustainable world. Since its launch in 2009, the Institute has developed a new model for innovation, collaboration, and technology translation within academia, breaking "silos" to enable collaborations that cross institutional and disciplinary barriers.
biomedical research. As a result, the boundaries between living and nonliving systems are literally breaking down.
The Wyss Institute for Biologically Inspired Engineering at Harvard
University 1 was founded in 2009 based on the belief that we have uncovered enough information about how Nature builds, controls, and manufactures from the nanoscale to the macroscale that we can now leverage these biological principles to develop new engineering innovations. We named this burgeoning field, "Biologically Inspired Engineering," to clarify how it differs from the more established disciplines of Bioengineering and Biomedical Engineering that continue to apply engineering principles to address biomedical challenges.
The Wyss Institute's mission is to discover the biological principles that Nature uses to build living things, and to harness these insights to create biologically inspired engineering innovations to advance human health and create a more sustainable world. Its foundation lies in the recognition that breakthrough discoveries cannot change the world if they never leave the laboratory. And thus, the Institute was designed to confront the challenge of translating technology advances across the academic-industrial interface, as much as it was created to catalyze the emergence of Biologically Inspired Engineering.
The Institute is similar to other academic research institutes in that it resides within the academic ecosystem of Harvard University. But the structure of the organization is specifically designed to overcome many of the challenges that in the past have held back technology innovation, intellectual property generation, and the commercialization of academic discoveries. This is crucial because these translation challenges continue to be a major stumbling block for universities and hospitals as they attempt to transition the discoveries their faculty and staff make into the marketplace where they can improve patients' lives.
In this article, we provide an overview of the organizational model we have developed to enable cross-disciplinary research collaborations, support technology innovation, augment intellectual property generation, and ensure efficient translation of discoveries into products that enter the marketplace in order to enhance human health.
| A N E W P AT H T O A CA DE M IC I N N OVA TI ON WI TH A TR A NS L A TI ON M I SSION
Companies tend to be optimized to generate intellectual property, protect its value, and develop products efficiently; however, as they are primarily focused on maximizing shareholder value, they often do not support pursuit of high-risk ideas that arise in their organizations. Difficulties in fostering innovative technology development are typically compounded in industry by most companies' unwillingness to change market direction and refocus operations due to the large capital investments they often have made for scale up and manufacturing of existing products in already well-defined market segments. In contrast, academia is a cauldron of innovation and creativity, but the focus is on publications with little focus or investment in intellectual property creation and its translation into useful products; thus, only few research advances have any direct impact on society at large.
The Wyss Institute was launched with a $125 million gift to Harvard University from Hansj€ org Wyss, which at the time was the largest single philanthropic gift in the University's history, and this was supplemented by contribution from Harvard as well. Based on our success within 5 years, our donor doubled his gift to $250 million. As a philanthropic entrepreneur who had been the CEO of a large medical device company, the donor shared this view and noted that "Big companies will not take risks. I try to convince my people to change directions, and they do not respond; it's like trying to turn a huge tanker. You academics do innovative things, but all you do is publish papers and make widgets. What I would like to see is an innovative startup in the world's greatest academic environment that will take risks and have positive near term impact on the world."
As a result, the Wyss Institute has pioneered a new model that combines the focus on applications, intellectual property generation, and commercialization commonly found in a start-up with the creative freedom and flexibility of academia. The measures of success that were established when the Institute was formed included academic ones, such as international recognition for our scientific leadership, and recruitment of world-class faculty, students, and fellows. However, we are also assessed based on the patent portfolio we generate and our ability to develop productive corporate alliances, licensing agreements, and new start-ups. Having our bioinspired technologies being sold or productized to achieve near-and long-term impact is the ultimate measure of the Institute's success.
In traditional academic settings, graduate students, postdoctoral fellows, and young faculty are not commonly trained to patent the technologies they invent, and their career advancement is not linked to their success at reducing innovations to practice. This is one of the major reasons why academic research produces a huge amount of information and innovations that are potentially exciting, but they rarely leave the laboratory, resulting in little or no positive impact on our broader society. The Wyss Institute aimed from its beginning to address this gap.
Given this focus, one of our major goals was to create a rich environment that is specifically designed to support interdisciplinary research and intellectual property generation, as well as prototype development, testing and validation, thereby de-risking technologies both technically and commercially. Our belief was that in addition to generating stronger intellectual property, successful maturation and de-risking of technologies led by a multidisciplinary collaborative team of world-leading scientists and engineers would attract funding from both industry and government agencies that are focused on development of disruptive technologies (e.g., DARPA, IARPA, DoD, etc.), thereby increasing the likelihood that these innovations will transition to the marketplace. However, to accomplish this, we realized that we must build our community from the bottom-up, because all creative endeavors are based on people.
To achieve these unique goals within an academic setting, the 
| M U L TI D ISC I P LI N AR Y RE SEA R CH A T A H I GH ER L EV EL
We launched the Institute by enlisting 14 of the most brilliant, innovative, and entrepreneurial faculty from Harvard University and our collaborating institutions as our founding core faculty members and over time augmented this group with new recruitments of both core and associate faculty (Table 1) co-locate to work on a common high value project application or major platform area of the Institute, examples of which are described below. In addition, we built cutting-edge capabilities that are accessible by all members of our community. One example is our unique machine shop, which is unlike most found in academia (and likely none in a medical school) as it is staffed by experienced, full-time engineers and houses state-of-the-art manufacturing equipment that enables fast prototyping and construction of virtually any type of device from the microscale to the macroscale. We also can build using a broad range of materials including those that are approved by the FDA for various medical applications. These capabilities allow members of our community to innovate and iterate at a rate that is uncommon for academia, which greatly enhances our ability to meet and beat milestones on both government-and industrial-funded technology development projects. we create these research platforms and initiatives is bio-inspired in that they are self-organizing, dynamic, and constantly evolving based on the shifting intellectual interests of our community members as well as the technical needs and challenges of the wider commercial marketplace.
| T HE I N S TI TU TE ' S PLATFORM FOCUS A R EA S A N D I N I TI A TI V ES
Platform and project self-assembly at the Institute results from the free flow of ideas and interactions among faculty and researchers, as well as administrative and business development staff. It is amplified by a culture that welcomes exploration and taking risks, which allows our staff and researchers to pursue their "out of the box" ideas without the stigma and fear of potential failure. Through its philanthropic funds, the Institute has the ability to readily support such ideas at their nascent stage, without the need for internal grant applications that typically stifle the excitement in organizations through long and bureaucratic decision points. Some of these ideas arising in our community may "fiz- intestine, kidney, bone marrow, liver, skin, heart, muscle, and brain. incremental advances, and they often generate their most exciting and visionary ideas long after grant applications are submitted. We turbocharge this approach by providing salary and supply funding to each of our core faculty members which allows them to hire two students or fellows who can pursue any creative technology concept or translation idea that is relevant to the field of biologically inspired engineering. We also teach our students, fellows, staff and faculty to disclose reports of Inc., and SlipChips Corp., and is a member of their scientific advisory boards.
LITERATURE CITED

